defence research and development canada has identified a number of problems for which they are seeking solutions. the list of 22 problems and corresponding s&t challenges have been copied and pasted into the attached document for your convenience but if any of these are of interest to you, please find the complete information at: https://buyandsell.gc.ca/procurement-data/tender-notice/pw-17-00800956

areas of s&t listed include but are not limited to:

·         artificial intelligence, machine learning or advanced/predictive data analytics

·         anonymization techniques

·         early detection and prevention of cyber‐attacks, resilience to cyber‐attacks, privacy or information protection in the telecommunications, transportation, and/or health sectors

·         traditional and non‐traditional cb agents

·         countering emerging infectious disease risk

·         standards to better position responders to plan for, deploy, and sustain the effective utilization of scarce resources from multiple agencies during resource critical events

·         applications of big and advanced analytics to reveal the correlations between crisis outcomes and community characteristics

·         technological solutions to support the development of multiagency approaches to reach at‐risk population segments

·         protecting deployed soldiers against hostile use of mini or small unmanned aerial vehicles

·         remote sensing based on soldier portable unmanned aerial vehicles (uav)

·         energy efficiencies

mitacs and the german academic exchange service (daad) have partnered to offer the rise-globalink research internship (rise-gri), which offers undergraduate 世界杯2022赛程表淘汰赛 at canadian universities the opportunity to undertake research at eligible german institutions.

rise-gri pairs canadian 世界杯2022赛程表淘汰赛 with three-month projects supervised by phd 世界杯2022赛程表淘汰赛 in germany.

• open to full-time undergraduates in biology, chemistry, physics, earth sciences, or engineering (or a closely related field) who have completed at least two years of a four- or five-year program
  • 世界杯2022赛程表淘汰赛 in quebec enrolled in a three-year undergraduate degree must have completed at least one year of their university program
• applications accepted until december 15, 2017
• competitive opportunity — only top-ranked 世界杯2022赛程表淘汰赛 are matched with projects
• projects must start between may 15 and july 9, 2018
• approved recipients receive $5,200 toward travel and accommodations

for questions about the application procedure, matching process, and internship placement, please contact rise-germany@daad.de. for any questions regarding the funding, please contact mitacs international at international@mitacs.ca.

university research awards are designed to encourage research at canadian universities in areas of interest to imperial oil's petroleum, petrochemical and energy resource development businesses. these areas include the fields of engineering, environmental, earth, chemical, and physical sciences.

awards for specific research projects are made to full-time faculty members to support research work carried out by university 世界杯2022赛程表淘汰赛 under their direction. 

individual awards are normally available in amounts ranging from $10,000 to $25,000 depending on budgets for the proposed research, availability of funds, and potential significance of the research as determined by imperial.

awards are made for one year and may be renewed annually for a maximum tenure of three years. 

for further information and applications, please visit our web site at imperial under the heading innovation and research/university grants/university research awards.  or go directly to university research awards. 

deadline for submission is december 15, 2017. 

please note that applications must be submitted in electronic format to email ura.sru@esso.ca.  pdf format is preferred.  preferred filename convention is applicantssurnameinitialsuniversityname.pdf

if you have any questions, please contact:

nancy bourque

university affairs administrator

sarnia technology applications & research (star), imperial

453 christina street south, sarnia, on n7t 8c8 canada |  room 40

ura.sru@esso.ca p 519.339.2617

the lyme disease research network grant is expected to:

1. build a national network on lyme disease to facilitate and support national collaboration among lyme disease stakeholders (researchers, clinicians, and patients) in resource and knowledge sharing:
   • mobilize, strengthen and build capacity in the lyme disease research community.
   • develop innovative multidisciplinary curricula and training opportunities for 世界杯2022赛程表淘汰赛 and professionals.
   • facilitate and support translation and dissemination of new knowledge from bench to bedside to population in order to:
     • improve clinical science and practice;
     • foster policy changes, leading to transformative and measureable improvements in the development and implementation of evidence-informed practices, policies, services, products and programs;
     • improve patient outcomes, access to care and quality, efficiency and effectiveness of health care.
2. develop a national cohort of patients in order to understand the association between serological and clinical phenomenology of lyme disease on a longitudinal basis (including a biobank creation and maintenance).

cihr's mandate is to excel, according to internationally accepted standards of scientific excellence, in the creation of new knowledge and its translation into improved health, more effective health services and products, and a strengthened health care system through a unique interdisciplinary structure made up of virtual institutes and initiatives.  to achieve these objectives, the institutes promote, and build upon, canada’s firm foundation of research excellence; and initiatives are created to investigate pressing health issues that are of strategic importance to our country.

one of the mechanisms for the institutes/initiatives to achieve their mandates is by offering planning and/or dissemination grants within the institute community support (ics) program. the planning and dissemination grants are intended to provide support for planning and/or dissemination activities consistent with the mandate of cihr and relevant to cihr institutes, or initiatives.

as part of the institute of population and public health’s transition to new leadership, the institute has undertaken a “listening tour” to engage researchers from across canada in order to better understand existing knowledge gaps and priority areas for population and public health research and to help update ipph’s strategic plan.  in response to these recent consultations, ipph is launching planning grants to support initial planning around two priority areas (described below).

research areas

this funding opportunity will support projects relevant to the following two research areas:

• building healthy cities
• ipph is developing preliminary ideas for strategic efforts to deepen canada’s scientific leadership in planning, designing and building healthy cities.
• as one part of initiating this process, ipph is providing funding for researchers to develop and formally pitch ideas for large-scale “big science” intervention research projects focused on building healthy cities. the goal is to encourage bold, out-of-the-box, blue-sky thinking for ambitious research projects. the ideas should be geared towards a single study that would be feasibly completed in a 5-7year time-frame with a maximum of $10 million cad (excluding the cost of implementing any interventions). the successful grantees will be brought together for each to pitch their ideas to inform possible future funding opportunities on healthy cities research.

note: the $10 million cad amount is provided as a guide for the development of comparable bold proposals and not meant as a funding commitment on the part of cihr.

• proposed ideas must fall within the mandate of ipph, which aims to improve the health of populations and promote health equity in canada and globally.

• artificial intelligence for population health
• cihr’s current strategic plan, health research roadmap ii, emphasizes a commitment to building canada’s capacity to innovate in the area of health research; enable health researchers to conduct “high-quality data-intensive research”; and “maximize opportunities for big data to advance knowledge and inform decisions that improve health, social and economic outcomes”.
• ipph will provide funding for planning activities/events that facilitate the development of partnerships, teams and/or grant applications for research projects exploring the use of artificial intelligence to answer population health questions that could subsequently be funded by cihr or other funders.
• applications must be focused on developing or applying artificial intelligence approaches for the purpose of addressing population health issues that are aligned with the mandate of the institute. applications focused on biomedical, clinical or health services research are not eligible for this funding opportunity.

the specific objective of this funding opportunity is to support projects that have the potential to significantly advance our understanding of cancer prevention and cancer control through the analysis of existing national or international large cohorts and/or administrative datasets specific to one of the three research areas above. such projects/analyses could lead to the identifications of prevention and treatment interventions, programs or protocols which contribute to the improvement of care and the reduction of morbidity and mortality.

the fy17 defense appropriations act provides $10 million (m) to the department of defense kidney cancer research program (kcrp) to support united states army medical research acquisition activity (usamraa).  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency (dha) j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp).

fy17 kcrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.

http://cdmrp.army.mil/funding/kcrp

consortium development award - letter of intent due december 20, 2017

·         an eligible principal investigator (who will be the consortium director) will be a faculty member at or above assistant professor (or equivalent) level. 

·         co-pis should be at or above assistant professor (or equivalent) level.

·         goal of the consortium development award is to ensure the establishment of the consortium infrastructure for future multi-institutional clinical trials

·         provides support to create a coordinating center and to establish the necessary collaborations at potential clinical trial sites for the development of a multi-institutional kidney clinical effort

·         minimum of three separate institutes: one coordinating center and at least two clinical sites (other than the coordinating center)

·         awardee will be eligible to apply for fy19 consortium award, if funds are available

·         maximum funding of $1.0 million total costs

·         maximum period of performance is 2 years

·         indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

idea development award – letter of intent due december 20, 2017

established investigators: 

·         independent investigators at or above the level of assistant professor (or equivalent) and 10 years or more from a terminal degree; or

·         early career investigators:

·         investigators at the level of assistant professor, instructor, or assistant research professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency or family medical leave) at the time of application submission deadline are eligible.

·         supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer.

·         supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer.

·         preliminary data is required

·         innovation and impact are the most important review criteria.

·         clinical trials are not allowed

·         areas of emphasis include:

·         microenvironment, metabolism, chromatin and gene regulation, rare cancers, screening, early detection, novel imaging technologies, liquid biopsy, biomarker development, prognosis, targeted therapies, immunotherapies, resistance, novel interventions, surgical, ablation, radiation, prognosis, managing toxicity, survivorship and patient experience, surveillance, genetic risk factors.

·         maximum funding of $400,000 in direct costs (plus indirect costs)

·         period of performance not to exceed 3 years

concept award – letter of intent due december 20, 2017

·         all investigators at or above the level of postdoctoral fellow (or equivalent) are eligible.

·         supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer

·         emphasis on innovation

·         clinical trials not allowed

·         preliminary data not allowed

·         blinded review

·         maximum funding of $75,000 for direct costs (plus indirect costs)

·         maximum period of performance is 1 year

translational research partnership – letter of intent due december 20, 2017

·         the initiating pi must be at or above the level of assistant professor or equivalent.

·         the partnering pi must be at or above the level of assistant professor or equivalent.  postdoctoral fellows are not eligible to be partnering pis

• ·         supports partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications
• ·         supports translational correlative studies
• ·         preliminary data required

·         clinical trials are not allowed

·         maximum funding of $600,000 for direct costs (plus indirect costs)

·         maximum period of performance is 3 years

·         indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

a pre-application (letter of intent) is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application (letter of intent) deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

applications must be submitted through the federal government’s single-entry portal, grants.gov.  for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the kcrp or other cdmrp-administered programs, please visit the cdmrp website (http://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

the fy17 defense appropriations act provides $10 million (m) to the department of defense kidney cancer research program (kcrp) to support united states army medical research acquisition activity (usamraa).  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency (dha) j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp).

fy17 kcrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.

http://cdmrp.army.mil/funding/kcrp

consortium development award - letter of intent due december 20, 2017

·         an eligible principal investigator (who will be the consortium director) will be a faculty member at or above assistant professor (or equivalent) level. 

·         co-pis should be at or above assistant professor (or equivalent) level.

·         goal of the consortium development award is to ensure the establishment of the consortium infrastructure for future multi-institutional clinical trials

·         provides support to create a coordinating center and to establish the necessary collaborations at potential clinical trial sites for the development of a multi-institutional kidney clinical effort

·         minimum of three separate institutes: one coordinating center and at least two clinical sites (other than the coordinating center)

·         awardee will be eligible to apply for fy19 consortium award, if funds are available

·         maximum funding of $1.0 million total costs

·         maximum period of performance is 2 years

·         indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

idea development award – letter of intent due december 20, 2017

established investigators: 

·         independent investigators at or above the level of assistant professor (or equivalent) and 10 years or more from a terminal degree; or

·         early career investigators:

·         investigators at the level of assistant professor, instructor, or assistant research professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency or family medical leave) at the time of application submission deadline are eligible.

·         supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer.

·         supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer.

·         preliminary data is required

·         innovation and impact are the most important review criteria.

·         clinical trials are not allowed

·         areas of emphasis include:

·         microenvironment, metabolism, chromatin and gene regulation, rare cancers, screening, early detection, novel imaging technologies, liquid biopsy, biomarker development, prognosis, targeted therapies, immunotherapies, resistance, novel interventions, surgical, ablation, radiation, prognosis, managing toxicity, survivorship and patient experience, surveillance, genetic risk factors.

·         maximum funding of $400,000 in direct costs (plus indirect costs)

·         period of performance not to exceed 3 years

concept award – letter of intent due december 20, 2017

·         all investigators at or above the level of postdoctoral fellow (or equivalent) are eligible.

·         supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer

·         emphasis on innovation

·         clinical trials not allowed

·         preliminary data not allowed

·         blinded review

·         maximum funding of $75,000 for direct costs (plus indirect costs)

·         maximum period of performance is 1 year

translational research partnership – letter of intent due december 20, 2017

·         the initiating pi must be at or above the level of assistant professor or equivalent.

·         the partnering pi must be at or above the level of assistant professor or equivalent.  postdoctoral fellows are not eligible to be partnering pis

• ·         supports partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications
• ·         supports translational correlative studies
• ·         preliminary data required

·         clinical trials are not allowed

·         maximum funding of $600,000 for direct costs (plus indirect costs)

·         maximum period of performance is 3 years

·         indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

a pre-application (letter of intent) is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application (letter of intent) deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

applications must be submitted through the federal government’s single-entry portal, grants.gov.  for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the kcrp or other cdmrp-administered programs, please visit the cdmrp website (http://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

postdoctoral enrichment program (pdep) provides a total of $60,000 over three years to support the career development activities for underrepresented minority postdoctoral fellows in a degree-granting institution (an institution includes its affiliated graduate and medical schools, hospitals and research institutions) in the united states or canada whose training and professional development are guided by mentors committed to helping them advance to stellar careers in biomedical or medical research.